Brief: Ampio Announces Early Positive Data In Phase 1 Trial Of Inhaled Ampion In COVID-19 Respiratory Distress

Ampio Pharmaceuticals

01/02/2021 14:22

Feb 1 (Reuters) - Ampio Pharmaceuticals Inc  AMPE.A :
    * AMPIO ANNOUNCES EARLY POSITIVE DATA IN PHASE 1 TRIAL OF
INHALED
AMPION IN COVID-19 RESPIRATORY DISTRESS
    * AMPIO PHARMACEUTICALS INC - SUBJECTS WHO RECEIVED AMPION
TREATMENT REQUIRED LESS OXYGEN THAN STANDARD OF CARE ALONE
    * AMPIO - SUBJECTS WHO GOT AMPION TREATMENT WERE STABLE OR
HAD
IMPROVEMENT ON ORDINAL SCALE FOR CLINICAL IMPROVEMENT VERSUS
STANDARD OF CARE PATIENTS
    * AMPIO PHARMACEUTICALS INC - AMPION IMPROVED ALL-CAUSE
MORTALITY
IN COVID-19 PATIENTS WITH RESPIRATORY DISTRESS COMPARED TO
STANDARD OF CARE
    * AMPIO PHARMACEUTICALS - THERE HAVE BEEN NO DRUG-RELATED
SERIOUS
ADVERSE EVENTS
    * AMPIO - IF SAFETY AND EFFICACY STUDY IS SUCCESSFUL, AND
PRODUCT
GETS REGULATORY APPROVAL, IS IN A POSITION TO BEGIN IMMEDIATE
MANUFACTURING

Source text for Eikon:  ID:nPnb1R84Ta 
Further company coverage:  AMPE.A 

 ((Reuters.Briefs@thomsonreuters.com;))